Osteoarthritis. Primary gonarthrosis, bilateral
Conditions
Interventions
Intervention 1: cases received 1500 mg/day of green tea leaves in 3 doses(Dineh Company with certification number:1228144011) plus 100 mg/day diclofenac. Intervention 2: control group: 100 mg Diclofen
Treatment - Drugs
cases received 1500 mg/day of green tea leaves in 3 doses(Dineh Company with certification number:1228144011) plus 100 mg/day diclofenac
control group: 100 mg Diclofenac
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients of both sexes with mild to moderate osteoarthritis of the knee, in the age group 40 to 75 years, referred to the Physical Medicine and Rehabilitation, Shiraz, Iran. Exclusion criteria: patients with severe osteoarthritis; patients suffering ischemic heart disease or heart failure; patients with renal function impairment; patients with hepatic failure; pregnant women; breastfeeding women; women who stop contraception techniques to become pregnant; patients who had a history of sensitivity to caffeine; patients whose diets are effective for weight loss or gain, and planned to decrease or increase their weight; patients who have recently begun the exercise to protect joints or changing their activity levels; patients treated with alkaline agents, for any reason, who was not able to discontinue their medications; patients treated with warfarin for any reason, that the patient was unable to stop his warfarin; patients with a history of gastrointestinal bleeding with non-steroidal anti-inflammatory drugs; patients who for any reason were not able to express their pain (eg patients with mental retardation or patients with Alzheimer's); patients who did not receive the necessary support for their drugs or they are not likely to be followed (eg, patients who were residents of older people centers ); patients who do not continure the trial: intolerable side effects for the patient (Gastrointestinal side effects such as increased gastric acid secretion, diarrhea or constipation, headache, palpitations, insomnia, irritability, restlessness);discontinuation of drugs consumption for any reason and not to follow treatment for any reason.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Function. Timepoint: at the beginning and 1 month after intervention. Method of measurement: WOMAC quastionaire.;Pain. Timepoint: at the beginning and 1 month after intervention. Method of measurement: WOMAC quastionaire.;Joint stiffness. Timepoint: at the beginning and 1 month after intervention. Method of measurement: WOMAC quastionaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSara Sadrneshin
Shiraz University of Medical Sciences
Outcome results
None listed